中文名 |
碘帕醇 |
---|---|
英文名 |
(S)-N,N′-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide |
中文别名 |
(S)-N,N’-双(1,3-二羟基丙-2-基)-5-[[(2S)-2-羟基丙酰]氨基]-2,4,6-三碘苯-1,3-二甲酰胺 |
英文别名 |
更多 |
描述 |
Iopamidol (B-15000; SQ-13396) 是非离子型,低渗透碘化造影剂。 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
相关类别 |
|
||||||||||||
溶解度 |
体外:
H 2 O:≥8.2mg / mL(10.55 mM) * “≥”表示可溶,但饱和度未知。
|
||||||||||||
储备液 |
|
||||||||||||
存储 |
4°C,避光
|
||||||||||||
运输 |
室温;可能会有所不同 |
||||||||||||
SMILES |
O=C(C1=C(I)C(NC([C@@H](O)C)=O)=C(I)C(C(NC(CO)CO)=O)=C1I)NC(CO)CO |
||||||||||||
参考文献 |
[1]. https://en.wikipedia.org/wiki/Iopamidol
|
||||||||||||
相关活性 小分子 |
磺丁醚-beta-环糊精 | 环孢菌素 | 2,7-二氯二氢代荧光黄二醋酸 | 1-甲基-4-苯基-1,2,3,6-四氢吡啶盐酸盐 | 4′,4”-双-2-咪唑啉-2-基对苯二丙烯酰苯胺二盐酸盐 | 乙莫克舍 | TD139 | Mitoquinone甲磺酸盐 | GSK2795039 | 5,5’,6,6’-四氯-1,1’,3,3’-四乙基苯并咪唑羰花青碘化物 | 胞内钙荧光探针 BAPTA-AM | AP20187 | GKT137831 | D-虫荧光素游离酸 | 野百合碱 |
密度 | 2.3±0.1 g/cm3 |
---|---|
沸点 | 785.3±60.0 °C at 760 mmHg |
熔点 | >320?C (dec) |
分子式 | C17H22I3N3O8 |
分子量 | 777.085 |
闪点 | 428.8±32.9 °C |
精确质量 | 776.854065 |
PSA | 188.45000 |
LogP | -2.09 |
外观性状 | 白色结晶粉末 |
蒸汽压 | 0.0±2.9 mmHg at 25°C |
折射率 | 1.739 |
储存条件 | -20?C Freezer |
碘帕醇毒性英文版
|
危险品运输编码 | NONH for all modes of transport |
---|---|
海关编码 | 2924299090 |
~96%
碘帕醇
60166-93-0
|
文献:EP883597 B1, ; Page/Page column 6-7 ; |
~%
碘帕醇
60166-93-0
|
文献:WO2012/175903 A1, ; |
碘帕醇上游产品? 3 | |
---|---|
|
|
碘帕醇下游产品? 0 |
海关编码 | 2924299090 |
---|---|
中文概述 | 2924299090. 其他环酰胺(包括环氨基甲酸酯)(包括其衍生物以及他们的盐). 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:30.0% |
申报要素 | 品名, 成分含量, 用途, 包装 |
Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Low contrast and radiation dose coronary CT angiography using a 320-row system and a refined contrast injection and timing method. J. Cardiovasc. Comput. Tomogr. 9(1) , 19-27, (2015)
Among CT scanners, 320-row instruments feature decreased photon energy and yield strong contrast enhancement. Consequently, the contrast medium (CM) dose can be reduced. The results of low-tube-voltag...
|
|
Influence of the motion correction algorithm on the quality and interpretability of images of single-source 64-detector coronary CT angiography among patients grouped by heart rate. Jpn. J. Radiol. 33(2) , 84-93, (2015)
We retrospectively investigated the effect of the motion correction algorithm (MCA) on image quality and interpretability by heart rate (HR) in coronary CT angiography (CCTA).For 105 patients (6 HR gr...
|
|
Evaluation of the predictive value of coronary artery calcium score for obstructive coronary artery disease in asymptomatic Korean patients with type 2 diabetes mellitus. Coron. Artery Dis. 26(2) , 150-6, (2015)
Compared with coronary computed tomographic angiography (CCTA), the coronary artery calcium score (CACS) may be limited in predicting adverse cardiovascular events in asymptomatic diabetic patients.We...
|
|
1,3-benzenedicarboxamide, N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[[(2S)-2-hydroxy-1-oxopropyl]amino]-2,4,6-triiodo- |
UNII:JR13W81H44 |
1,3-benzenedicarboxamide, N,N’-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo- |
N,N’-Bis(1,3-dihydroxy-2-propanyl)-2,4,6-triiodo-5-(lactoylamino)isophthalamide |
N,N’-Bis(1,3-dihydroxy-2-propanyl)-5-{[(2S)-2-hydroxypropanoyl]amino}-2,4,6-triiodoisophthalamide |
Iopamiron |
EINECS 262-093-6 |
N,N’-bis[2-hydroxy-1-(hydroxyméthyl)éthyl]-5-{[(2S)-2-hydroxypropanoyl]amino}-2,4,6-triiodobenzène-1,3-dicarboxamide |
(S)-N,N’-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide |
1,3-benzenedicarboxamide, N1,N3-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[[(2S)-2-hydroxy-1-oxopropyl]amino]-2,4,6-triiodo- |
N,N’-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-{[(2S)-2-hydroxypropanoyl]amino}-2,4,6-triiodbenzol-1,3-dicarboxamid |
1,3-Benzenedicarboxamide, N,N-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo- |
N,N’-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-{[(2S)-2-hydroxypropanoyl]amino}-2,4,6-triiodobenzene-1,3-dicarboxamide |
Iopamidol |
1,3-Benzenedicarboxamide, N,N’-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo- |
Isovue |
MFCD00867931 |
1,3-Benzenedicarboxamide, N,N-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[[(2S)-2-hydroxy-1-oxopropyl]amino]-2,4,6-triiodo- |
5-(a-Hydroxypropionylamino)-2,4,6-triiodoisophthalic Acid Di(1,3-dihydroxyisopropylamide) |
Iopamiro |
N,N’-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxypropanoyl)amino]-2,4,6-triiodobenzene-1,3-dicarboxamide |
(s)-n,n’-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-2,4,6-triiodo-5-lactamidoisophthalamide |
N,N’-bis(1,3-dihydroxypropan-2-yl)-5-{[(2S)-2-hydroxypropanoyl]amino}-2,4,6-triiodobenzene-1,3-dicarboxamide |
(S)-N,N’-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide |
Solutrast |
iomapidol |
N,N’-Bis(1,3-dihydroxypropan-2-yl)-5-{[(2S)-2-hydroxypropanoyl]amino}-2,4,6-triiodoisophthalamide |
Jopamiro |